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Abstract
Background: Primary sclerosing cholangitis (PSC) is a rare chronic cholestatic liver disease often associated with
inflammatory bowel diseases (IBD). Current epidemiological data are limited to studies of predominantly Caucasian
populations. Our aim was to define the epidemiology of PSC in a large, ethnically diverse US population.
Methods: The Northern California Kaiser Permanente (KP) database includes records from over 3 million people
and was searched for cases of PSC between January 2000 and October 2006. All identified charts were reviewed
for diagnosis confirmation, IBD co-morbidity, and major natural history endpoints.
Results: We identified 169 (101 males) cases fulfilling PSC diagnostic criteria with a mean age at diagnosis of 44
years (range 11-81). The age-adjusted point prevalence was 4.15 per 100,000 on December 31, 2005. The age-
adjusted incidence per 100,000 person-years was not significantly greater in men 0.45 (95% CI 0.33 - 0.61) than
women 0.37 (95% CI 0.26 - 0.51). IBD was present in 109/169 (64.5%) cases and was significantly more frequent in
men than women with PSC (73.3% and 51.5%, respectively, p = 0.005). The cumulative average yearly mortality rate
was 1.9%. Age and serum sodium, creatinine and bilirubin at diagnosis and albumin at last entry were identified as
significant factors associated with death, liver transplant or cholangiocarcinoma.
Conclusions: The incidence and prevalence of PSC observed in a representative Northern California population are
lower compared to previous studies in Caucasian populations and this might reflect differences in the incidence of
PSC among various ethnic groups.
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Background
Primary sclerosing cholangitis (PSC) is a chronic chole-
static liver disease of unknown etiology [1] characterized
by classic findings of multiple segmental strictures in the
intra- and extra-hepatic bile ducts secondary to inflamma-
tion and obliterative fibrosis. Less common, the small duct
PSC subtype is characterized by a normal cholangiogram
and a better prognosis [2]. Inflammatory bowel disease
(IBD) is found in 65-90% of PSC cases and though usually
classified as ulcerative colitis (UC), the IBD associated
with PSC has a unique phenotype including pancolitis, ilei-
tis, rectal sparing and is often asymptomatic [3,4].
Both environmental and genetic risk factors have been
associated with PSC susceptibility, in some cases being
common to the IBD background, as in the case of
smoking [5-7]. Interestingly, the association of PSC with
the human leukocyte antigen DR3-B8-A1 haplotype
found in Northern European populations [8,9] has not
been reproduced in Italian or Brazilian PSC cohorts sug-
gesting that genetic risks for PSC may vary between
populations [10,11]. In African-Americans patients listed
for liver transplantation in the US, we have recently
shown that PSC is associated with HLA-B8, but not
HLA-DR3 suggesting a common genetic risk factor near
the HLA-B locus [12].
The overall risk and clinical presentation of PSC also
appears to vary between populations. Population-based
studies in different geographical areas of primarily
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Northern European ancestry have demonstrated annual
incidence rates ranging between 0.41 and 1.2 per
100,000 person-years [13-18]. In populations of Asia,
Southern Europe and Alaska, the prevalence of PSC
appears much lower and with a lower frequency of
IBD [19-25]. In contrast, small case series suggested that
IBD patients of African descent are at greater risk of
PSC, [26,27] although this has not been recapitulated in
a larger study [28]. Our own analysis of liver transplant
registrants in the US identified African-American race
as a significant risk factor for PSC patients even after
controlling for socioeconomic and other factors [12].
The aim of the present study was to determine whether
the ethnic differences identified in the liver transplant
registrant population extends to PSC patients in general
by measuring the incidence, prevalence, natural history,
and IBD co-morbidity in a large health maintenance
organization consisting of over 3 million subjects repre-
senting an ethnically diverse population.
Methods
Study population
We utilized the membership database of the northern
California Kaiser-Permanente Medical Care Plan (KP).
This is a prepaid health maintenance organization that
provides medical care to approximately 25-30 percent of
the population primarily located in urban areas of the
greater San Francisco Bay and Sacramento metropolitan
areas. Comparison of KP membership data and census
data demonstrate that the KP membership is closely
representative of the Northern California population in
many demographic variables with the exception of small
differences in education and income [29]. A random
sample of 5,080, members in 2001 was comprised of
64% non-Hispanic white, 12% Hispanic, 6% African-
American, 16% Asian and 3% other [30]. According to
2000 US census data the population of the twelve coun-
ties served by KP was 51.1% non-Hispanic white, 19.8%
Hispanic, 7.5% African-American, 17.0% Asian and 4.6%
other. The study was conducted with the approval of
the Kaiser Foundation Research Institute Institutional
Review Board.
Case ascertainment
After approval by the Institutional Review Board, the
northern California KP database was searched for PSC
diagnoses entered between January 2000 and October
2006. Unlike ICD-9 coding which does not allow for a
specific code for PSC, the KP database utilizes a unique
code for PSC. The charts of all subjects identified were
then reviewed for biochemical, cholangiographic, and/or
histological evidence of PSC. Inclusion criteria consisted
of radiographic evidence of PSC on cholangiogram or
histological evidence on liver biopsy. When neither test
was positive for PSC the case was excluded from further
analysis despite the PSC coding. Small duct PSC was
defined as histological findings consistent with PSC and
a normal cholangiogram. Exclusion criteria included sec-
ondary causes of biliary sclerosis. Natural history end-
points included liver transplant, cholangiocarcinoma,
and death. Additional collected data included age, gen-
der, date of diagnosis, laboratory studies at diagnosis,
means of diagnosis, and the presence of IBD. Data on
race and ethnicity were recorded when mentioned in
the medical record but were available on less than half
of the cases and were not included in this analysis.
Statistical Analysis
Age- and/or gender-adjusted rates and 95 percent confi-
dence intervals were calculated using direct standardiza-
tion with the age and/or gender distribution of the 2000
US population as the reference population. To compare
the female and male groups for the (overall) age-
adjusted incidence rates of PSC, we used the method of
Dobson et al. (1991) to calculate the confidence interval
(CI) for each gender group [31]. We used time to any of
three events; death, cholangiocarcinoma, or liver trans-
plant, as a response variable and used the Cox propor-
tional hazards model to investigate what factors had a
statistically significant effect on hazard rates. Two-sided
Fisher’s exact test and Pearson’s exact test were used to
compare proportions and crude incidence rates, respec-
tively. Wilcoxon-Mann-Whitney test was used to com-
pare continuous variables. All analyses were two-tailed
and a p-value of < 0.05 was considered as statistically
significant.
Results
Patient Characteristics
We identified 169 patients who fulfilled the diagnostic
criteria for PSC during the study period (Table 1). Of
these 101 (59.8%) were males. The mean age at diagno-
sis was 44 years (range 11-81). There were 12 (7%) cases
diagnosed before the age of 18 years. Age groups at
diagnosis in adult cases included 49 (30%) at ages 18-35
years, 82 (50%) at ages 36-65 years, and 21 (13%) at
ages >65 years. Five (3%) cases were considered to have
small duct PSC based upon a normal appearing cholan-
giogram and liver histology consistent with PSC.
IBD was present in 109 (64.5%) PSC cases and was
classified as UC in 95, CD in 13, and indeterminate colitis
in one case. Patients with PSC and IBD were significantly
younger with a mean (± standard deviation) age of 41.1 ±
1.6 years compared to 49.4 ± 2.4 years in PSC cases with-
out IBD (P = 0.005). A significant difference in the fre-
quency of IBD by gender was observed with IBD
diagnosed significantly more frequently in men compared
to women (73.3% and 51.5%, respectively, P = 0.005). No
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significant differences in age at diagnosis were observed
between genders.
Prevalence and Incidence
In December 2005 there were 140 cases of PSC alive
and included in the database. The KP membership at
this time consisted of 3,236,094 members giving an
overall age-adjusted prevalence of 4.03 per 100,000 (95%
CI 3.36 - 4.70). Gender specific age-adjusted prevalence
was 4.92 (95% CI 3.86 - 5.97) and 3.19 (95% CI 2.36 -
4.02) for men and women, respectively.
Eighty-one of the 169 cases were incident between
January 2000 and October 2006. The overall age-
adjusted PSC incidence was 0.41 (95% CI 0.32 to 0.51)
per 100,000 person-years. Stratified by gender, the age-
adjusted incidence rate for males was numerically
greater than females (0.45 (95% CI 0.33 - 0.61) and 0.37
(95% CI 0.26 - 0.51) per 100,000 person-years, respec-
tively). Figure 1 illustrates the adjusted incidence rates
by age groups and gender.
Outcomes
Twenty-three (13%) PSC cases underwent liver trans-
plantation, 9 of which were performed during the study
period. Seven (4%) PSC cases were diagnosed with
cholangiocarcinoma and 25 (13%) deaths occurred dur-
ing the study period with 16 being liver-related (Table 2).
Regression analyses based on the Cox proportional
hazards model demonstrated that age at diagnosis (p =
0.02), serum sodium at diagnosis (p = 0.02), creatinine at
diagnosis (p = 0.03), bilirubin at diagnosis (p = 0.003),
albumin at diagnosis (p = 0.004), and albumin at last
entry (p = 0.005) were statistically significant factors
associated with death, liver transplantation or cholangio-
carcinoma (Table 3). More specifically, the hazard rate
was significantly increased with the increase of age at
diagnosis, sodium at diagnosis and creatinine at diagnosis
and significantly decreased with the increase of albumin
at diagnosis and the increase of albumin at last entry.
Race (White versus non-White) was not a significant
factor in this analysis.
Table 1 Demographic, biochemical, and clinical
characteristics of 169 PSC cases diagnosed within a
northern Californian HMO in the 2000-2006 period
Age at diagnosis, years 44.2 ± 17.4 (11-81)
Males, n (%) 101 (59.8)
Ethnicity,n (%)
White 51 (30.2)
African American 15 (8.9)
Hispanic 9 (5.3)
Asian/Pacific Islander 3 (1.8)
Other/Unknown 91 (53.8)
Laboratory Values at Diagnosis
Alkaline Phosphatase, IU/L 283.4 ± 256.8 (30 - 1355)
Aspartate Aminotransferase, IU/L 66 ± 65.7 (13 - 407)
Alanine Aminotransferase, IU/L 70.3 ± 71.9 (11 - 339)
Total bilirubin, g/dL 2.3 ± 3.7 (0.2 - 19.7)
Serum albumin, g/dL 3.8 ± 0.8 (1.3 - 5.1)
International Normalized Ratio 1.1 ± 0.2 (0.9 - 2.7)
MELD 9.6 + 4.1 (6.4 - 27.4)
IBD, n (%) 109 (64.5)
Ulcerative colitis 95 (56.2%)
Crohn’s disease 13 (7.7%)
Indeterminate colitis 1 (0.6%)
Outcomes, n
Liver Transplantation 23
Cholangiocarcinoma 7
Death 25
All continuous variables are expressed as mean ± standard deviation (range).
Figure 1 Adjusted Incidence Rates of Primary Sclerosing
Cholangitis in Northern California by Age and Gender, 2000-
2006.
Table 2 Cause of death in PSC patients from 2000-2006
Cause Number of Deaths
Liver-related
Liver failure 7
Hepatorenal syndrome 4
Cholangiocarcinoma 3
Liver Cancer, unspecified 1
Cholangitis/Sepsis 1
Non Liver-related
Colon Cancer 2
Myocardial infarction 2
Squamous Cell Cancer 1
Pulmonary fibrosis 1
Pulmonary embolism 1
Urosepsis 1
Unknown 1
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Discussion
The results of our study, which to our knowledge is the
largest population-based case-finding study on PSC,
demonstrate a prevalence of 4.03 cases per 100,000 and
an incidence of 0.41 per 100,000 person-years. Similar
to other populations, the majority of cases are males
and IBD, particularly UC, is associated with PSC and is
more frequent in males compared to females. We also
identified several variables associated with the major dis-
ease outcomes, i.e. death, liver transplantation and
cholangiocarcinoma.
PSC is a rare cholestatic disorder of unknown etiology
for which there is no effective therapy. Although the pre-
valence of the disease appears to vary widely in different
ethnic and racial groups, most population-based studies
of PSC have been in relatively homogeneous populations
in terms of ethnic and racial composition [13-17]. We
sought to determine the prevalence and incidence of PSC
in an ethnically and racially diverse population. The
Northern California region is comprised of many differ-
ent ethnic and racial groups with non-Hispanic whites
making up only a slight majority of 51.1% based on 2000
US Census data. Because a strong association between
PSC and IBD has always been observed to a lesser or
greater degree and the risk of IBD varies between ethnic
and racial groups, the prevalence of PSC might be simi-
larly affected. Alternatively, the genetic basis of PSC
appears to be independent of IBD genetic risk factors
suggesting that there may not be a strict correlation
between rates of IBD and PSC [9,32].
Similar to other PSC cohorts, we observed a predomi-
nance of males with a mean age at diagnosis in the mid-
forties. The frequency of IBD was similar to other studies
and we identified a significantly lower frequency of IBD
in women with PSC, which is consistent with the findings
of other smaller studies [33,34]. These rates should be
Table 3 Univariate Analysis of Proportional Hazards Regression to Death, Cholangiocarcinoma or Liver Transplant
Characteristic Hazard ratio (HR) 95% HR confidence interval P-value
Gender 1.065 (0.515, 2.200) 0.87
Race 0.835 (0.3, 2.327) 0.73
White
Non-white
Age at diagnosis 1.029 (1.004, 1.054) 0.02
IBD 0.657 (0.315, 1.373) 0.26
No
Yes
Lab measurement at study entry
Sodium 1.144 (1.022, 1.28) 0.02
Creatinine 4.034 (1.116, 14.584) 0.03
Alkaline phosphatase 1.000 (0.999, 1.002) 0.47
Alanine aminotransferase 0.997 (0.993, 1.001) 0.14
Aspartate aminotransferase 0.996 (0.992, 1.001) 0.13
Bilirubin 1.122 (1.039, 1.211) 0.003
INR 1.569 (0.874, 2.818) 0.13
Albumin 1.013 (0.938, 1.095) 0.74
MELD 1.066 (0.998, 1.139) 0.06
Lab measurement at last entry
Sodium 0.941 (0.804, 1.101) 0.45
Creatinine 1.873 (0.711, 4.932) 0.20
Alkaline phosphatase 1.001 (0.999, 1.003) 0.51
Alanine aminotransferase 0.999 (0.992, 1.006) 0.76
Aspartate aminotransferase 1.000 (0.994, 1.006) 0.99
Bilirubin 1.09 (0.982, 1.210) 0.11
International normalized ratio 1.335 (0.440, 4.045) 0.61
Albumin 0.329 (0.153, 0.709) 0.005
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considered a lower limit of the actual frequency. Some
subjects did not have a record of a colonoscopy and often
times the IBD of PSC is asymptomatic [3,35,36]. Whether
the gender differences we observed are due to differences
in true IBD prevalence or in rates of diagnosis warrant
further investigation.
One of the most striking differences in our study com-
pared to prior studies is the lower incidence and preva-
lence of PSC in this population compared to populations
of Olmstead County, Alberta, Wales and Norway. This
would seem to contradict the assertion by some authors
that there is an increasing incidence of PSC diagnoses
since the widespread use of endoscopic retrograde cholan-
giography and magnetic resonance cholangiography was
introduced. One possible explanation for this discrepancy
could be the result of under diagnosis leading to an under-
estimation of the true disease prevalence. PSC is a rare dis-
ease that may not be recognized by a clinician without
particular skills or awareness. In addition, because there is
not an effective therapy for PSC and liver test abnormal-
ities are frequent in IBD, some clinicians may prefer not
to confirm the diagnosis of PSC when it is suspected, par-
ticularly if an invasive test is needed. It is notable that our
estimates of PSC prevalence and incidence are similar to
those of another recent large study of a subset of the Brit-
ish population (total population of 2,027,909), which like
the present study, was not based on one or a few hospitals
with a particular interest in PSC [17].
Alternatively, this discrepancy might be due to a lower
incidence of IBD, particularly UC, within Northern Cali-
fornia. However, a recent study of the KP database deter-
mined that the incidence and prevalence of UC and CD
is similar to or greater than that of Olmstead County,
Manitoba and Europe [37]. Nevertheless, differences in
the ethnic distribution between IBD and the total popula-
tion have been noted[37,38]. A prior study of a subset of
this population in Oakland, CA reported that non-Hispa-
nic whites made up only 64% of the total population but
represented 80% of the IBD cases [38]. In contrast,
Hispanics and Asian Americans comprised a dispropor-
tionately smaller percentage of the IBD cases compared
to the total membership. In the more recent study of the
total KP population, African Americans and Asians con-
stituted 16% and 9% of the total IBD population, respec-
tively, compared to 6% and 16% of the membership[37].
Further, other studies suggested that PSC is rare in Asia
and that African Americans are at greater risk of devel-
oping extra-intestinal manifestation of IBD, including
PSC [23,24,26-28]. Ethnicity was documented in the
medical record in fewer than half of the cases preventing
us from drawing conclusions about the effect of ethnicity
on the prevalence or incidence of PSC.
The strengths of our study include the use of compre-
hensive paper and electronic medical records to ascertain
details of the PSC cases, the representative population of
the northern California KP and the community care set-
ting as opposed to a tertiary referral center. In contrast to
the UK study, we were able to confirm each case of PSC
based upon accepted diagnostic criteria. In addition, the
size of the population allowed us to more accurately esti-
mate the incidence and prevalence of a relatively rare dis-
ease. Therefore, these results are likely to be more
representative of the total population.
Our study did have some weaknesses. The lack of ethnic
and racial data in a large subset of patients limited our
ability to address risk assessment or determination of
prognostic factors for the natural course of disease depen-
dent on race. We also note that not all patients with PSC
had colonoscopies and therefore our estimates of IBD are
likely underestimates of the actual rates. Finally, although
this population is generally representative of the total
population of Northern California, there is some skewing
away from the upper and lower income groups.
Conclusions
We have reported on the largest population based study
of PSC to date and the only one to include an ethnically
diverse population. Although the common features of
age at diagnosis, male predominance and presence of
IBD are similar to other studies, we observed lower PSC
prevalence and incidence rates than reported in most
other populations. Further studies in this or other simi-
lar populations will be helpful in determining if there
are significant differences in PSC susceptibility and clini-
cal outcomes between ethnic groups.
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